Identification of Key Blood Molecular Markers for Immunotherapy
To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.
Squamous Cell Carcinoma|Adenocarcinoma|Neoplasms
PROCEDURE: phlebotomy
To identify and evaluate the presence of pre-existing immunity related markers in peripheral human blood, to identify patients who may respond to IL-12 immunotherapy, 3 years
To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.